NEW YORK, NY / ACCESSWIRE / April 13, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avenue Therapeutics, Inc. (“Avenue” or “the Company”) (NASDAQ:ATXI). Investors who purchased Avenue securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/atxi.
The investigation concerns whether Avenue and certain of its officers and/or directors have violated federal securities laws.
On April 13, 2021, Avenue issued a press release “announc[ing] that the U.S. Food and Drug Administration (‘FDA’) was still reviewing its New Drug Application (‘NDA’) for IV tramadol and had not provided a decision regarding the NDA.” The Company’s resubmitted NDA for the treatment, which followed a complete response letter from the FDA in 2020, had been assigned an action date of April 12, 2021. On this news, Avenue’s stock price fell sharply during intraday trading on April 13, 2021.
If you are aware of any facts relating to this investigation, or purchased Avenue shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/atxi. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/640225/Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-of-Avenue-Therapeutics-Inc-ATXI-Investigation